Neuropore Therapeutics is a biotechnology company dedicated to developing disease-modifying therapies for neurodegenerative disorders, including Alzheimer's disease and Progressive Supranuclear Palsy (PSP).
- Tau Pathology: Targeting tau protein misfolding and aggregation
- Protein Homeostasis: Modulating cellular mechanisms for protein clearance
- Neuroinflammation: Addressing inflammatory components of neurodegeneration
- NPT200-11: Tau aggregation inhibitor in development for tauopathies
- Preclinical programs targeting alpha-synuclein and TDP-43
The company's platform focuses on:
- Small molecule inhibitors of pathological protein aggregation
- Enhancement of cellular clearance mechanisms (autophagy, ubiquitin-proteasome)
- Modulation of neuroinflammatory pathways
- Academic partnerships with leading neurodegeneration research centers
- Pharmaceutical collaborations for clinical development
- Research funding from foundations focused on tauopathies
- Based in San Diego, California
- Team with expertise in drug discovery and neurodegenerative disease research
This page provides information about Neuropore Therapeutics.